Immunoclassification of Psoriasis: a Strategy for Precision Medicine

Zhejiang University

Status: Enrolling

Conditions: Psoriasis; Immunoclassification

Treatments: Biological: adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate

Study type: Interventional

Funder types: Other

Identifiers

NCT05503875

2022-0205

Details and patient eligibility

About

Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.

Full description

Psoriasis is a heterogeneous condition that can affect skin and other structures. Over the past decade, considerable advances have been made both in our understanding of the pathogenesis of psoriasis and in the revolutionized immunotherapy of its diverse manifestations. Psoriasis heterogeneity and its cutaneous microenvironment is the leading cause of resistance in patients.

Novel approaches, including single-cell RNA sequencing technology and CyTOF, are proposed as methodological solutions. By their combination with immunotherapy, we can specifically evaluate the mechanism of psoriasis in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of cytokines, immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and assisting the dissection of the critical immune-metabolic pathways in this complex disease. We aim to improve short-term and long-term precision treatment strategies for patients with psoriasis.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1.18 to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of psoriasis≥6 months 4.Patients must be candidate for systemic therapy 5.Informed consent must be obtained 6.For female, ß-hCG test is negative and contraception is accepted

Exclusion criteria

1. Having severe infections, including hepatitis, HIV and tuberculosis
2. Having significant allergies to biological agents
3. Having a history of malignancy
4. Refusal of contraception
5. Having serious or unstable/uncontrolled illnesses

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

treatment

Experimental group

Description:

Patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.

Treatment:

Biological: adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate